Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.

ABSTRACT:

Aims

Among patients with heart failure (HF) and reduced ejection fraction (HFrEF), those with atrial fibrillation (AF) may respond differently to certain treatments than patients without AF. We investigated the efficacy and safety of dapagliflozin in patients with HFrEF with and without AF in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF). We also examined the effect of dapagliflozin on new-onset AF.

Methods and results

The primary outcome was the composite of an episode of worsening HF (HF hospitalization or urgent HF visit requiring intravenous therapy) or cardiovascular death. Of the 4744 patients randomized, 1910 (40.3%) had 'any AF' (history of AF or AF on enrolment electrocardiogram). Compared with placebo, dapagliflozin reduced t

SUBMITTER: Butt JH 

PROVIDER: S-EPMC10234442 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature